SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

MONOVISC

ANIK·Anika Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market, MONOVISC is an approved, commercialized single-injection viscosupplement sold within Anika's Commercial Channel (no pending approval for this product).
Why 3/10
MONOVISC is an already-approved, marketed product with no hard, dated binary catalyst of its own in the next ~12 months, the company's upcoming regulatory catalysts (Cingal NDA submission, Hyalofast PMA decision) belong to other assets, so per the rubric an approved drug with no pending decision caps at 3-5; with MONOVISC being one of several products in a ~$200M company, it scores 3.
Actionable Insight NEUTRAL

MONOVISC is not the near-term trade for ANIK, it is the baseline commercial cash generator, so watch quarterly "Commercial Channel" revenue and gross-margin trends as the read-through on the OA franchise. The share-price drivers to track instead are the dated catalysts on other Anika assets: the Cingal NDA submission timeline and Hyalofast PMA updates (Hyalofast was removed from 2027 revenue guidance due to FDA timing uncertainty). Note the stock is extended (+138% over 12 months, RSI-14 ~78.7, forward P/E ~47), so upside is partially priced in.

Price Chart

Loading chart...

Executive Summary

MONOVISC is Anika Therapeutics' approved single-injection hyaluronic-acid viscosupplement for knee osteoarthritis, part of Anika's osteoarthritis pain-management franchise (with multi-injection ORTHOVISC and pipeline product CINGAL). It is a mature commercial product with no pending regulatory decision of its own: Q2 2026 results showed the broader franchise driving record Commercial Channel revenue of $13.9M (+17% YoY) within a $32.6M total-revenue quarter that beat consensus, with raised FY2026 guidance. The stock has run +138% over 12 months (price ~$19.28, near its 52-week high), but the actual binary catalysts are other assets (Cingal NDA, Hyalofast PMA), making MONOVISC a steady cash-flow contributor rather than a near-term catalyst.

How It Works

MONOVISC is a single injection of a thick, gel-like hyaluronic acid (a natural lubricating molecule found in joint fluid) into the knee. It restores the cushioning and viscosity of the joint fluid ("viscosupplementation") to relieve pain from knee osteoarthritis, a mechanical lubrication treatment, not a drug that changes disease course.

Trial Status

No active Phase 2/3 registrational trial is tracked for MONOVISC in local databases, it is a marketed product generating revenue (Anika's Q2 2026 filing analysis lists MONOVISC among the company's commercial drug names, alongside ORTHOVISC, CINGAL, HYALOFAST and INTEGRITY). Anika's pending regulatory work (Cingal NDA, Hyalofast PMA) is on separate pipeline assets.

The Two-Sided Case

▲ Bull Case3
MONOVISC sits in a commercial portfolio that is accelerating: Q2 2026 revenue of $32.6M (+16% YoY) beat the $29.2M consensus, GAAP EPS of $0.24 beat the $0.03 estimate, and Commercial Channel revenue hit a record $13.9M (+17% YoY), with FY2026 EBITDA-margin guidance raised to 13%-17% (from 5%-10%).
Anika is a focused, profitable player in early-intervention orthopedics / OA pain management (self-described 'global leader in osteoarthritis pain management'), and its hyaluronic-acid franchise benefits from an aging population needing non-surgical knee pain options.
Supportive tape around the name: analyst consensus is strongly buy-leaning (4 Buy + 3 Strong Buy vs 1 Hold, 0 Sell) with a mean price target of $21 (~9% above the current ~$19 price), 13F shows fresh accumulation (Assenagon +35.3%, Wealth Enhancement +55.1% in 2026-Q2), and short interest is modest at ~2.63% of estimated shares outstanding (settlement 2026-07-15, down 16% period-over-period).
▼ Bear Case3
MONOVISC itself has no hard, dated catalyst: its regulatory binary passed long ago, and the company's actual pending decisions, Cingal's NDA (still awaiting completion of two required studies) and Hyalofast's PMA (removed from 2027 revenue guidance due to FDA timing uncertainty), are on other products, so MONOVISC cannot drive a binary move.
The single-injection hyaluronic-acid knee-injection market is mature, competitive and reimbursement-sensitive, with multiple rival viscosupplements; payer scrutiny of the class is a structural headwind to pricing and volume.
Valuation/technical stretch and balance-sheet caution: forward P/E ~47, RSI-14 ~78.7 (overbought), the stock is up 110.7% over 6 months and +138% over 12 months; operating cash flow was -$5.5M YTD and cash fell to $38.4M at June 30, 2026 from $57.5M at Dec 2025 (share repurchases + inventory build).

Upcoming Catalysts

  • Cingal NDA submission, company guided to submission upon completion of two required studies (bioequivalence study initiation on track; Q3 earnings call is the venue for timeline updates)
  • Hyalofast PMA decision/timing, FDA deficiency-letter resolution; removed from 2027 revenue guidance, creating binary risk
  • Quarterly earnings (Q3 2026), Commercial Channel revenue and gross-margin read-through for the MONOVISC/ORTHOVISC franchise
  • Barrington Research and B. Riley Securities maintain Buy/Outperform ratings; watch for price-target revisions after the guidance raise

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Anika Therapeutics, Inc. 8-K ANIK ·Originating report

Sources · 8

Hover a chip for the title
1 sec.gov2 sec.gov3 globenewswire.com4 globenewswire.com5 globenewswire.com6 globenewswire.com7 globenewswire.com8 globenewswire.com